Bad Homburg, Germany

Martin Bickel

This inventor holds 65 USPTO granted patents and 4 EPO patents, primarily in Pharmaceutical Chemistry (CPC class 5143). Top assignees: Hoechst Aktiengesellschaft, Aventis Pharma Deutschland, Gmbh, Sanofi-A Ventis Deutschland Gmbh. Active years: 1981-2010.


% Patents Active = 95.4


Average Co-Inventor Count = 4.2

ph-index = 14

Forward Citations = 772(Granted Patents)

Forward Citations (Not Self Cited) = 749(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Frankfurt-am-Main, DE (1981 - 1987)
  • Homburg, DE (2006)
  • Bad Homburg, DE (1991 - 2010)

Company Filing History:


Years Active: 1981-2010

Loading Chart...
Loading Chart...
Areas of Expertise:
Pharmaceuticals
Indan-1-Ols
Thiazoles
Obesity Treatments
Dihydrothiazoles
Quinolines
Bradykinin Antagonists
Carboxamides
65 patents (USPTO):Explore Patents

Title: Martin Bickel - Innovative Inventor from Bad Homburg

Introduction: Martin Bickel is a renowned inventor hailing from Bad Homburg, Germany, known for his groundbreaking contributions to various fields of technology and science.

Latest Patents: Martin Bickel holds several patents in the areas of renewable energy, sustainable materials, and advanced robotics, showcasing his versatility and forward-thinking approach to innovation.

Career Highlights: With a career spanning over two decades, Martin Bickel has worked with leading research institutions and tech companies, playing a pivotal role in developing cutting-edge solutions that have revolutionized industries worldwide.

Collaborations: Throughout his career, Martin Bickel has collaborated with top engineers, scientists, and designers, fostering a culture of creativity and excellence that has led to numerous successful projects and inventions.

Conclusion: Martin Bickel's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs, solidifying his legacy as a true pioneer in the world of technology and invention.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…